[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:donor-specific-antibody":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Donor-specific Antibody",3,2,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06948097","Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies",[12],"Phase 1","RECRUITING","2026-08-26T02:17:00.709807Z","2026-07-05T05:32:16.707499Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06398457","Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies",[20],"Early Phase 1","2026-08-26T02:15:53.461103Z","2026-05-05T02:43:27.839395Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT05058170","Renal Allograft Fibrosis Study",[],"ENROLLING_BY_INVITATION","2026-08-26T02:18:40.612983Z","2026-06-16T05:54:07.975556Z"]